Truist raised the firm’s price target on Autolus Therapeutics to $11 from $10 and keeps a Buy rating on the shares. The firm is revising its revenue model for Adult ALL and anticipates Obe-cel to potentially surpass $600M in peak sales across the U.S. and E.U. as it emerges as the leading player in the market, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics announces acceptance of MAA by EMA for obe-cel
- Autolus Therapeutics Announces Board Leadership Changes
- Autolus chairman John Johnson steps down, Mike Bonney succeeds
- Autolus Therapeutics Announces Changes to its Board of Directors
- Autolus files to sell 33.33M American Depositary Shares for holders
